Asian Pac J Cancer Prev. 2017 Oct 26;18(10):2683-2688. doi: 10.22034/APJCP.2017.18.10.2683.

Genetic Polymorphisms of Fas/FasL Promoter Associated with Hepatitis C cirrhosis and HCC.

Asian Pacific journal of cancer prevention : APJCP

Sally Abed, Mohamed El-Dosoky, Maysaa El Sayed Zaki, Mohamed EL-Shafey

PMID: 29072392 PMCID: PMC5747390 DOI: 10.22034/APJCP.2017.18.10.2683

Abstract

Aim: The present study was performed to determine any associations of genetic polymorphisms of Fas/FasL promoter regions, at Fas670 and Fas1377 and FasL844, with hepatitis C cirrhosis and HCC, with a focus on severity of disease. Methods: Totals of 120 patients with cirrhosis and 101 with hepatocellular carcinoma (HCC) were enrolled. All had chronic HCV infection as indicated by positive anti-HCV antibodies and positive HCV RNA on real time PCR. One hundred healthy control subjects were also included in the study. Patients were subjected to full clinical, radiological and histopathological examinations. In addition to routine laboratory tests for liver function tests, Fas670 and Fas1377 and FasL844 genetic polymorphisms of Fas/FasL promoter regions were assessed by RFLP-PCR (restriction fragment length polymorphism with polymerase chain reaction). Results: Significant higher levels of the AG genotype in Fas670 and Fas1773 were observed in patients with cirrhosis and HCC (P=0.0001) as compared to control subjects. In addition, the CC genotype in FASL844 was also more common in patients (P=0.01). Furtehrmore, there was a significant association of substitution of A by G alleles in Fas670 and Fas1773 with advanced BCA staging (P=0.02, P=0.0001 respectively) and larger tumor size >5cm (P=0.01, P=0.0001 respectively) and in Fas670 with advanced pathological grading (P=0.0001). Moreover the CC genotype of FASL844 was significantly linked with advanced BCA, large tumor size >5cm and advanced pathological grading (P=0.0001). Conclusion: The findings of the present study highlight associations of genetic polymorphisms of promoter regions in Fas and Fas L with cirrhosis and HCC associated with chronic HCV. Support was also obtained for the conclusion that single nucleotide polymorphisms of the Fas/ FasL system impact on clinical and histopathological grading of HCCs. Further large scale studies are recommended for confirmation.

Creative Commons Attribution License

Keywords: HCV; HCC; genetic polymorphism in promoter regions of Fas/FasL; cirrhosis

References

1. Semin Ultrasound CT MR. 2002 Feb;23 (1):19-36 - PubMed
2. Comp Hepatol. 2010 Jan 05;9(1):1 - PubMed
3. Cancer Res. 2003 Aug 1;63(15):4327-30 - PubMed
4. Gynecol Oncol. 2005 Oct;99(1):113-8 - PubMed
5. J Hepatol. 2011 Mar;54(3):566-76 - PubMed
6. J Immunol. 2003 Jan 1;170(1):132-8 - PubMed
7. Int J Oncol. 2005 Feb;26(2):467-73 - PubMed
8. Expert Opin Ther Targets. 2005 Oct;9(5):1031-44 - PubMed
9. J Clin Virol. 2005 Oct;34(2):140-6 - PubMed
10. World J Gastrointest Oncol. 2010 Jun 15;2(6):259-64 - PubMed
11. Mol Immunol. 1997 Jun;34(8-9):577-82 - PubMed
12. Annu Rev Pathol. 2006;1:23-61 - PubMed
13. Expert Opin Biol Ther. 2010 Nov;10(11):1563-72 - PubMed
14. Cancer J. 2007 Jul-Aug;13(4):233-7 - PubMed
15. World J Surg. 2004 Aug;28(8):792-6 - PubMed
16. Cancer Lett. 2009 Dec 1;286(1):69-79 - PubMed
17. Hepat Mon. 2012 Nov;12(11):e6132 - PubMed
18. Immunol Invest. 2008;37(2):163-70 - PubMed
19. Braz J Med Biol Res. 2004 Nov;37(11):1689-705 - PubMed
20. Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1081-8 - PubMed
21. Virus Res. 2003 Nov;97(2):103-10 - PubMed
22. Medscape J Med. 2008 Jun 03;10(6):130 - PubMed
23. World J Gastroenterol. 2003 Dec;9(12):2671-5 - PubMed
24. Gut. 2005 Jul;54(7):1024-33 - PubMed
25. Gastroenterology. 2005 Jun;128(7):1898-906 - PubMed
26. J Viral Hepat. 2008 Jul;15(7):515-22 - PubMed

Publication Types

• Journal Article